Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after similar to 5 Years of Tamoxifen
Autores principales: | Goss, P, Mamounas, E, Jakesz, R, Markopoulos, C, Dowsett, M, Peto, R, Godwin, J, Davies, C |
---|---|
Formato: | Conference item |
Publicado: |
2009
|
Ejemplares similares
-
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
por: Dowsett, M, et al.
Publicado: (2009) -
Variation in use of adjuvant tamoxifen.
por: Davies, C, et al.
Publicado: (1998) -
Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani D, et al.
Publicado: (2021-11-01) -
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
por: Gelber, R, et al.
Publicado: (1996) -
Aromatase inhibitors versus tarnoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies
por: Ingle, J, et al.
Publicado: (2009)